EVFM News and Press, Evofem Biosciences Inc.

Aditxt (NASDAQ: ADTX) , a company dedicated to discovering, developing and deploying promising health innovations, along with its wholly owned subsidiary Adifem Inc., and Evofem Biosciences Inc. (OTCQB: EVFM) have amended and restated their previously announced merger agreement. Accor...

Evofem Acquires SOLOSEC, an FDA-Approved Single-Dose Treatment for Bacterial Vaginosis and Trichomoniasis Aditxt, Inc. (“Aditxt”) (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, announces this past Friday, July 12...

2024-06-27 10:57:17 ET This company is striving to change the narratives around women's healthcare and offering solutions that reinforce and improve them. And shares are responding positively to a recent partnership announcement. Women's health innovator %EvofemBiosciences Inc. (OTC...

Hello Alpha Partners with Evofem to Offer Phexxi® as a Hormone-Free Contraception Solution on its Platform for Women's Healthcare PR Newswire — Leading telemedicine company expands offering with hormone-free birth control as GLP-1 medication usage increases ...

2024-06-11 11:00:35 ET More on Evofem Biosciences Seeking Alpha’s Quant Rating on Evofem Biosciences Financial information for Evofem Biosciences Read the full article on Seeking Alpha For further details see: Evofem gains on new U.S. patent coveri...

Evofem Announces Issuance of New U.S. Patent Covering Phexxi Composition of Matter PR Newswire -- Issuance of U.S. Patent No. 11,992,472 Further Strengthens Evofem's Intellectual Patent Portfolio -- -- Newly issued patent is Evofem's fifth covering Hormone-Free "I...

Aditxt (NASDAQ: ADTX) recently provided Evofem Biosciences Inc. (OTCQB: EVFM) $1 million in consideration for reinstating and amending the merger agreement, as amended, between the companies. Aditxt agreed to invest an additional $2.5 million in Evofem by July 1, and the companies are working ...

2024-05-15 07:16:38 ET More on Evofem Biosciences Seeking Alpha’s Quant Rating on Evofem Biosciences Financial information for Evofem Biosciences Read the full article on Seeking Alpha For further details see: Evofem Biosciences GAAP EPS of -$0.16,...

Evofem Biosciences Announces Financial Results for the First Quarter of 2024 PR Newswire SAN DIEGO , May 15, 2024 /PRNewswire/ -- The company behind the hormone-free contraceptive Phexxi® (lactic acid, citric acid and potassium bitartrate) , Evofem ...

Evofem Strengthens Phexxi Intellectual Property with New Composition of Matter Patent From USPTO PR Newswire -- Application allowed with broad method claims that are Orange Book-listable -- -- Once issued, this will be Evofem's fifth patent covering Hormone-Free "In th...